C4 Therapeutics Latest News
- 03-11 AInvest WireCCC Intelligent Solutions: Stock Price to Remain Rangebound Until Revenue Growth Improves
- 03-10 AInvest WireC4 Therapeutics: Despite Cheap Valuation, Risk Remains High
- 03-06 AInvest WireLeonardo and Baykar form joint venture for unmanned aerial systems
- 03-04 AInvest WireCCC Intelligent Solutions Holdings' Earnings May Not Tell Whole Story
- 03-03 AInvest WireC4 Therapeutics Shows Signs of Reversal, Analysts Expect Better Earnings
- 03-03 NasdaqC4 Therapeutics (CCCC) Loses -21.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
- 03-01 MarketWatchC4 Therapeutics: Promising Clinical Developments and Strategic Plans Justify Buy Rating
- 02-28 MarketWatchAnalysts Offer Insights on Healthcare Companies: Agilent (A) and C4 Therapeutics (CCCC)
- 02-28 AInvest ExclusiveCCCC Latest Report
- 02-27 MarketWatchC4 Therapeutics Reports Strong 2024 Financial Performance and Clinical Progress
- 02-27 AInvest NewsFinancial Results | C4 Therapeutics 2024 Full Year Revenue USD 35.58 Million Net Loss USD 105.32 Million
- 02-27 AInvest WireC4 Therapeutics (CCCC) Loses -26.18% in 4 Weeks, Here's Why a Trend Reversal May Be Around the Corner
- 02-27 AInvest WireCCC Intelligent Solutions Names Tim Welsh as New President
- 02-27 AInvest WireC4 Therapeutics Q4 EPS of -$0.49 Beats Estimates, Revenue of $5.2M Surpasses Expectations
- 02-27 MarketWatchC4 Therapeutics reports Q4 EPS (49c), consensus (45c)
- 02-27 MarketWatchC4 Therapeutics sees cash runway into 2027
- 02-27 AInvest WireC4 Therapeutics Q4 revenue down 56%, FY24 cash $267.3mln
- 02-27 NasdaqC4 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
- 02-26 AInvest WireCCC Intelligent Solutions Appoints Tim Welsh as President to Lead Digital Transformation of Insurance and Collision Repair Industries.
Show More News